These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

111 related articles for article (PubMed ID: 39642328)

  • 1. Cancer-Control Outcomes of Patients With Metastatic Castration-Resistant Prostate Cancer With
    Wenzel M; Koll F; Hoeh B; Humke C; Reis H; Wild P; Steuber T; Graefen M; Tilki D; Sabet A; Gröner D; Chun FKH; Mandel P
    JCO Precis Oncol; 2024 Dec; 8():e2400645. PubMed ID: 39642328
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Outcomes for Patients with Metastatic Castration-Resistant Prostate Cancer and Liver Metastasis Receiving [
    Muniz M; Sartor O; Orme JJ; Koch RM; Rosenow HR; Mahmoud AM; Andrews JR; Kase AM; Riaz IB; Belge Bilgin G; Thorpe MP; Kendi AT; Johnson GB; Ravi P; Kwon ED; Childs DS
    J Nucl Med; 2024 Dec; 65(12):1932-1938. PubMed ID: 39477495
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Genomic Correlates of Prostate-Specific Membrane Antigen Expression and Response to
    Raychaudhuri R; Mo G; Tuchayi AM; Graham L; Gulati R; Pritchard CC; Haffner MC; Yezefski T; Hawley JE; Cheng HH; Yu EY; Grivas P; Montgomery RB; Nelson PS; Chen DL; Hope T; Iravani A; Schweizer MT
    JCO Precis Oncol; 2024 Apr; 8():e2300634. PubMed ID: 38662984
    [TBL] [Abstract][Full Text] [Related]  

  • 4. SPECT/CT in Early Response Assessment of Patients with Metastatic Castration-Resistant Prostate Cancer Receiving
    Demirci RA; Gulati R; Hawley JE; Yezefski T; Haffner MC; Cheng HH; Montgomery RB; Schweizer MT; Yu EY; Nelson PS; Chen DL; Iravani A
    J Nucl Med; 2024 Dec; 65(12):1945-1951. PubMed ID: 39510589
    [No Abstract]   [Full Text] [Related]  

  • 5. Comparison of Two Modern Survival Prediction Tools, SORG-MLA and METSSS, in Patients With Symptomatic Long-bone Metastases Who Underwent Local Treatment With Surgery Followed by Radiotherapy and With Radiotherapy Alone.
    Lee CC; Chen CW; Yen HK; Lin YP; Lai CY; Wang JL; Groot OQ; Janssen SJ; Schwab JH; Hsu FM; Lin WH
    Clin Orthop Relat Res; 2024 Dec; 482(12):2193-2208. PubMed ID: 39051924
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Prognostic Significance of Baseline Clinical and [68Ga]Ga-PSMA PET Derived Parameters on Biochemical Response, Overall Survival, and PSA Progression-Free Survival in Metastatic Castration-Resistant Prostate Cancer (mCRPC) Patients Undergoing [177Lu]Lu-PSMA Therapy.
    Jafari E; Manafi-Farid R; Ahmadzadehfar H; Salek F; Jokar N; Keshavarz A; Divband G; Dadgar H; Zohrabi F; Assadi M
    Nuklearmedizin; 2024 Dec; 63(6):347-358. PubMed ID: 39227023
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Efficacy and safety of rechallenge with [
    Santo G; Di Santo G; Sviridenko A; Bayerschmidt S; Wirth L; Scherbauer F; Lehmann P; von Guggenberg E; Decristoforo C; Heidegger-Pircher I; Bektic J; Virgolini I
    Eur J Nucl Med Mol Imaging; 2024 Dec; 52(1):354-365. PubMed ID: 39225826
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comparison of Posttherapy 4- and 24-Hour [
    Swiha M; Pathmanandavel S; Papa N; Sabahi Z; Li S; Zheng A; Khan S; Ayers M; Sharma S; Crumbaker M; Nguyen A; Chan L; Ayati N; Emmett L
    J Nucl Med; 2024 Dec; 65(12):1939-1944. PubMed ID: 39477497
    [TBL] [Abstract][Full Text] [Related]  

  • 9. PSMA PET/CT for treatment response evaluation at predefined time points is superior to PSA response for predicting survival in metastatic castration-resistant prostate cancer patients.
    Kleiburg F; de Geus-Oei LF; Luelmo SAC; Spijkerman R; Goeman JJ; Toonen FAJ; Smit F; van der Hulle T; Heijmen L
    Eur J Radiol; 2024 Dec; 181():111774. PubMed ID: 39442347
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Falls prevention interventions for community-dwelling older adults: systematic review and meta-analysis of benefits, harms, and patient values and preferences.
    Pillay J; Gaudet LA; Saba S; Vandermeer B; Ashiq AR; Wingert A; Hartling L
    Syst Rev; 2024 Nov; 13(1):289. PubMed ID: 39593159
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Progression-directed Therapy in Oligoprogressive Castration-resistant Prostate Cancer: Final Results from the Prospective, Single-arm, Phase 2 MEDCARE Trial.
    Rans K; Joniau S; Berghen C; Goffin K; Dumez H; Haustermans K; De Meerleer G
    Eur Urol Oncol; 2024 Dec; 7(6):1441-1450. PubMed ID: 38664137
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Correlation analyses of radiographic progression-free survival with clinical and health-related quality of life outcomes in metastatic castration-resistant prostate cancer: Analysis of the phase 3 VISION trial.
    Morris MJ; de Bono J; Nagarajah J; Sartor O; Wei XX; Nordquist LT; Koshkin VS; Chi KN; Krause BJ; Herrmann K; Rahbar K; Vickers A; Mirante O; Ghouse R; Fizazi K; Tagawa ST
    Cancer; 2024 Oct; 130(20):3426-3435. PubMed ID: 39031642
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Detection of tumour heterogeneity in patients with advanced, metastatic castration-resistant prostate cancer on [
    Pabst KM; Mei R; Lückerath K; Hadaschik BA; Kesch C; Rawitzer J; Kessler L; Bodensieck LS; Hamacher R; Pomykala KL; Fanti S; Herrmann K; Fendler WP
    Eur J Nucl Med Mol Imaging; 2024 Dec; 52(1):342-353. PubMed ID: 39207485
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Tamoxifen for adults with hepatocellular carcinoma.
    Naing C; Ni H; Aung HH
    Cochrane Database Syst Rev; 2024 Aug; 8(8):CD014869. PubMed ID: 39132750
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Medication Prescription Policy for US Veterans With Metastatic Castration-Resistant Prostate Cancer: Causal Machine Learning Approach.
    Gopukumar D; Menon N; Schoen MW
    JMIR Med Inform; 2024 Nov; 12():e59480. PubMed ID: 39561358
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Abiraterone acetate plus prednisolone with or without enzalutamide for patients with metastatic prostate cancer starting androgen deprivation therapy: final results from two randomised phase 3 trials of the STAMPEDE platform protocol.
    Attard G; Murphy L; Clarke NW; Sachdeva A; Jones C; Hoyle A; Cross W; Jones RJ; Parker CC; Gillessen S; Cook A; Brawley C; Gilson C; Rush H; Abdel-Aty H; Amos CL; Murphy C; Chowdhury S; Malik Z; Russell JM; Parkar N; Pugh C; Diaz-Montana C; Pezaro C; Grant W; Saxby H; Pedley I; O'Sullivan JM; Birtle A; Gale J; Srihari N; Thomas C; Tanguay J; Wagstaff J; Das P; Gray E; Alzouebi M; Parikh O; Robinson A; Montazeri AH; Wylie J; Zarkar A; Cathomas R; Brown MD; Jain Y; Dearnaley DP; Mason MD; Gilbert D; Langley RE; Millman R; Matheson D; Sydes MR; Brown LC; Parmar MKB; James ND;
    Lancet Oncol; 2023 May; 24(5):443-456. PubMed ID: 37142371
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Biosimilar monoclonal antibodies for cancer treatment in adults.
    Galvao TF; Livinalli A; Lopes LC; Zimmermann IR; Silva MT
    Cochrane Database Syst Rev; 2024 Nov; 11(11):CD013539. PubMed ID: 39607013
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Lamotrigine versus levetiracetam or zonisamide for focal epilepsy and valproate versus levetiracetam for generalised and unclassified epilepsy: two SANAD II non-inferiority RCTs.
    Marson AG; Burnside G; Appleton R; Smith D; Leach JP; Sills G; Tudur-Smith C; Plumpton CO; Hughes DA; Williamson PR; Baker G; Balabanova S; Taylor C; Brown R; Hindley D; Howell S; Maguire M; Mohanraj R; Smith PE
    Health Technol Assess; 2021 Dec; 25(75):1-134. PubMed ID: 34931602
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The prognostic role of pan-immune inflammation value in patients with metastatic castration resistance prostate cancer treated with Lutetium-177 (
    Yazgan SC; Yekeduz E; Araz M; Bolek H; Kucuk NO; Urun Y
    Prostate; 2025 Jan; 85(1):90-96. PubMed ID: 39344207
    [TBL] [Abstract][Full Text] [Related]  

  • 20. PET-Based TheraP Eligibility and Outcomes of VISION-Eligible Patients with Metastatic Castration-Resistant Prostate Cancer Who Received
    Demirci RA; Ghodsi A; Gulati R; Behnia S; Nelson PS; Cheng HH; Yezefski TA; Haffner MC; Hawley JE; Montgomery RB; Yu EY; Schweizer MT; Chen DL; Iravani A
    J Nucl Med; 2024 Nov; ():. PubMed ID: 39542703
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.